9-ING-41

• CAT Number: I017651
• CAS Number: 1034895-42-5
• Molecular Formula: C₂₂H₁₃FN₂O₅
• Molecular Weight: 404.35
• Purity: ≥95%
• Target: Stem Cell/Wnt
• Storage: Store at -20°C
• IUPAC Name: 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
• InChI: InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
• InChIKey: FARXPFGGGGLENU-UHFFFAOYSA-N
• SMILES: CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F

9-ING-41（Cat No.:I017651）is a potent and selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), an enzyme involved in regulating various cellular processes, including apoptosis, proliferation, and differentiation. By inhibiting GSK-3β, 9-ING-41 disrupts key signaling pathways associated with cancer cell survival, making it a promising candidate for cancer treatment. Preclinical studies have shown its effectiveness in reducing tumor growth and enhancing the efficacy of other anticancer therapies. 9-ING-41 is being investigated for its potential in treating a range of malignancies, including glioblastoma, pancreatic cancer, and sarcomas.

Reference

[1]. Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63.[2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.[3]. Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.[4]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724.